ENTX
Entera Bio Ltd. NASDAQ Listed Jun 28, 2018$1.26
-4.55%
vs $1.32
Mkt Cap $62.0M
52w Low $0.91
15.2% of range
52w High $3.22
50d MA $1.21
200d MA $1.79
P/E (TTM)
-5.3x
EV/EBITDA
—
P/B
4.7x
Debt/Equity
0.0x
ROE
-87.3%
P/FCF
-8.2x
RSI (14)
—
ATR (14)
—
Beta
1.54
50d MA
$1.21
200d MA
$1.79
Avg Volume
201.0K
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Kiryat Hadassah Minrav Building · Jerusalem 9112002 · IL
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 27, 2026 | AMC | -0.09 | -0.07 | +22.2% | 1.13 | -9.7% | -11.5% | +11.0% | +2.7% | +10.5% | -5.6% | — |
| Nov 14, 2025 | AMC | -0.09 | -0.07 | +22.2% | 2.71 | +0.4% | -1.1% | -3.0% | +1.9% | -2.6% | -1.9% | — |
| Aug 8, 2025 | AMC | -0.11 | -0.06 | +45.5% | 1.82 | -0.5% | +3.3% | +0.5% | +2.6% | +1.5% | +1.5% | — |
| May 9, 2025 | AMC | -0.07 | -0.06 | +14.3% | 2.15 | +2.3% | +0.0% | -7.0% | -1.0% | +1.5% | +1.0% | — |
| Mar 28, 2025 | AMC | -0.08 | -0.06 | +25.0% | 1.75 | -2.3% | -2.9% | -4.1% | +3.1% | -2.4% | -2.4% | — |
| Nov 8, 2024 | AMC | -0.05 | -0.08 | -60.0% | 1.72 | +0.0% | -1.2% | -1.8% | +0.0% | +6.6% | -2.8% | — |
| Aug 9, 2024 | AMC | -0.06 | -0.06 | +0.0% | 1.60 | +3.8% | -2.5% | +4.5% | -3.7% | +0.0% | +3.8% | — |
| May 10, 2024 | AMC | -0.06 | -0.05 | +16.7% | 2.46 | +2.0% | -4.9% | +7.3% | +4.4% | -0.8% | -6.2% | — |
| Mar 8, 2024 | AMC | -0.08 | -0.07 | +12.5% | 1.39 | +2.2% | +5.0% | -1.4% | +0.7% | -5.5% | +0.0% | — |
| Nov 14, 2023 | AMC | -0.09 | -0.08 | +11.1% | 0.72 | +0.0% | +1.4% | -0.1% | +0.1% | +0.0% | +0.0% | — |
| Aug 11, 2023 | AMC | -0.07 | -0.08 | -14.3% | 0.74 | +0.0% | -17.6% | -1.6% | +5.0% | -5.2% | -0.2% | — |
| May 5, 2023 | AMC | -0.12 | -0.08 | +33.3% | 0.82 | -4.4% | +7.3% | +3.9% | -1.5% | +0.0% | +4.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.12 | $1.15 | +2.7% | +2.7% | -1.7% | +1.8% | +3.5% | -7.6% |
| Feb 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.04 | $1.07 | +2.9% | +27.9% | +9.0% | +13.1% | -7.3% | -1.3% |
| Mar 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.95 | $1.96 | +0.5% | +0.0% | +0.0% | -1.0% | +1.0% | +0.0% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.72 | $1.72 | +0.0% | -1.2% | -1.8% | +0.0% | +6.6% | -2.8% |
| Oct 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.87 | $1.80 | -3.7% | -4.3% | +0.6% | -2.2% | +1.1% | +4.5% |
| Sep 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.92 | $1.90 | -1.0% | +4.7% | -5.5% | -3.7% | +1.1% | -0.5% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.60 | $1.66 | +3.8% | -2.5% | +4.5% | -3.7% | +0.0% | +3.8% |
| Jun 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.10 | $2.03 | -3.3% | -1.0% | +0.5% | -4.3% | +2.0% | +2.5% |
| May 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.34 | $2.34 | +0.0% | +7.3% | +4.4% | -0.8% | -6.2% | -5.7% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.46 | $2.51 | +2.0% | -4.9% | +7.3% | +4.4% | -0.8% | -6.2% |
| Apr 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.87 | $1.90 | +1.6% | -0.5% | -7.0% | +9.8% | +4.7% | -2.0% |
| Dec 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.68 | $0.68 | +0.3% | +1.6% | -2.8% | +0.4% | -2.5% | +0.2% |
| Sep 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.66 | $0.70 | +5.6% | +4.1% | -1.0% | +0.7% | -3.6% | +6.1% |
| Sep 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.63 | $0.68 | +8.7% | +6.2% | -1.3% | +4.1% | -1.0% | +0.7% |
| May 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.82 | $0.78 | -4.4% | +7.3% | +3.9% | -1.5% | +0.0% | +4.4% |
| Apr 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.00 | $1.02 | +2.0% | -2.0% | -6.1% | -6.4% | +4.1% | +0.4% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.03 | $1.01 | -1.9% | +2.9% | +27.4% | -9.6% | -4.9% | -13.8% |
| Sep 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.40 | $1.45 | +3.6% | -2.1% | -0.7% | +4.4% | -2.1% | +0.7% |
| Jul 19 | B. Riley Securities | Maintains | Buy → Buy | — | $1.40 | $1.49 | +6.4% | +3.6% | +4.1% | +25.2% | -4.2% | -2.8% |
| Jun 16 | B. Riley Securities | Maintains | Buy → Buy | — | $3.73 | $3.99 | +7.0% | +11.5% | +24.8% | -14.8% | +3.2% | -1.5% |
| Mar 22 | Aegis Capital | Maintains | Buy → Buy | — | $4.57 | $4.44 | -2.8% | +3.3% | -11.9% | -11.5% | +8.7% | -10.5% |
| Aug 3 | Maxim Group | Maintains | Buy → Buy | — | $5.08 | $5.15 | +1.4% | +9.8% | -9.5% | +8.3% | -7.7% | -2.0% |
No insider trades available.
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Governance / Corporate
BVF Partners' agreement with Entrix likely signals strategic backing or governance changes that could validate the company's direction and potentially attract institutional support, benefiting long-term shareholders.
Apr 3
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Entera's EB613 osteoporosis program achieved significant milestone progress in 2025, potentially validating its oral peptide platform and supporting future revenue growth and stock appreciation.
Mar 27
8-K · 7.01
! Medium
Entera Bio Ltd. -- 8-K 7.01: Regulation FD Disclosure
Entera Bio advanced its osteoporosis candidate EB613 toward FDA approval by submitting a Phase 3 protocol, potentially positioning the company for a key registrational trial in a large market.
Mar 4
8-K · 5.02
!!! Very High
Entera Bio Ltd. -- 8-K 5.02: Executive Change
Entera Bio Ltd. appointed Geno J. Germano as Class III director effective February 4, 2026, strengthening board governance and potentially signaling strategic direction changes.
Feb 9
8-K · 5.02
!!! Very High
Entera Bio Ltd. -- 8-K 5.02: Executive Change
Steven D. Rubin's appointment as a Class III director at Entera Bio (ENTX) effective February 2026 expands board oversight and may signal management's confidence in governance structure during potential strategic initiatives.
Feb 4
Data updated apr 25, 2026 7:16am
· Source: massive.com